8-K

 

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of Report (Date of Earliest Event Reported): May 22, 2008

Gilead Sciences, Inc.
__________________________________________
(Exact name of registrant as specified in its charter)

Delaware	0-19731	94-3047598
_____________________ (State or other jurisdiction	_____________ (Commission	______________ (I.R.S. Employer
of incorporation)	File Number)	Identification No.)
333 Lakeside Drive, Foster City, California		94404
_________________________________ (Address of principal executive offices)		___________ (Zip Code)

Registrant’s telephone number, including area code: 650-574-3000

Not Applicable
______________________________________________
Former name or former address, if changed since last report

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

[  ]  Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
[  ]  Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
[  ]  Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
[  ]  Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Item 8.01 Other Events.

On May 22, 2008, John C. Martin, PhD, Chairman and Chief Executive Officer of Gilead Sciences, Inc., a Delaware corporation (the Company), entered into a new stock trading plan under Rule 10b5-1 of the Securities Exchange Act of 1934 (Rule 10b5-1). James M. Denny, the lead independent director of the Board of Directors of the Company, Paul Berg, Ph.D., a member of the Company’s Board of Directors, John F. Milligan, PhD, President and Chief Operating Officer, Kevin Young, Executive Vice President, Commercial Operations, Gregg H. Alton, Senior Vice President and General Counsel, and Kristen M. Metza, Senior Vice President, Human Resources, previously established stock trading plans under Rule 10b5-1, and certain other officers and directors of the Company may do so in the future. A copy of the press release is filed as Exhibit 99.1 to this report.

The information in this Form 8-K and the exhibit attached hereto shall not be deemed "filed" for purposes of Section 18 of the Securit ies Exchange Act of 1934, as amended (the Exchange Act), or otherwise subject to the liabilities under that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, regardless of any general incorporation language in such filing.

Item 9.01 Financial Statements and Exhibits.

(d) Exhibits

Exhibit
Number Description
99.1 Press Release, issued by Gilead Sciences, Inc. on May 22, 2008

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

	Gilead Sciences, Inc.
May 22, 2008	By:	/s/ John F. Milligan, Ph.D.
		Name: John F. Milligan, Ph.D.
		Title: President and Chief Operating Officer

Exhibit Index

Exhibit No.	Description
99.1	Press Release, issued by Gilead Sciences, Inc. on May 22, 2008

EX-99.1

CONTACTS:	Susan Hubbard, Investors (650) 522-5715
	Amy Flood, Media (650) 522-5643

For Immediate Release

GILEAD SCIENCES’ CHAIRMAN AND CHIEF EXECUTIVE OFFICER
ESTABLISHES RULE 10B5-1 STOCK TRADING PLAN

Foster City, CA, May 22, 2008 – Gilead Sciences, Inc. (Nasdaq: GILD) today announced the establishment of a new stock trading plan under Rule 10b5-1 of the Securities Exchange Act of 1934 on May 22, 2008 by John C. Martin, PhD, Chairman and Chief Executive Officer of Gilead. Commencing in September 2008, Dr. Martin’s plan provides for the exercise and sale of certain options each month on pre-determined dates through July 2010.

The transactions under the plan are disclosed publicly through Form 144 and Form 4 filings with the Securities and Exchange Commission. James M. Denny, Gilead’s lead independent director of the Board, Paul Berg, PhD, a member of Gilead’s Board of Directors, John F. Milligan, PhD, President and Chief Operating Officer, Kevin Young, Executive Vice President, Commercial Operations, Gregg H. Alton, Senior Vice President and General Counsel, and Kristen M. Metza, Senior Vice President, Human Resources, maintain stock trading plans under Rule 10b5-1, and other officers and directors of the company may do so in the future.

Rule 10b5-1 allows insiders to adopt written plans for trading securities in a non-discretionary, pre-scheduled manner in order to avoid concerns about initiating stock transactions when the insider may be aware of non-public information. Such plans also allow insiders to diversify their holdings and to minimize the market effect of stock sales by spreading them out over time.

About Gilead
Gilead Sciences is a biopharmaceutical company that discovers, develops and commercializes innovative therapeutics in areas of unmet medical need. The company’s mission is to advance the care of patients suffering from life-threatening diseases worldwide. Headquartered in Foster City, California, Gilead has operations in North America, Europe and Australia.

# # #

For more information on Gilead Sciences, please visit www.gilead.com or
call the Gilead Public Affairs Department at 1-800-GILEAD-5 (1-800-445-3235).